 | • レポートコード：MRC2312MG11733 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、61ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の内因性ペプチド物質市場規模と予測を収録しています。・世界の内因性ペプチド物質市場：売上、2018年-2023年、2024年-2029年 ・世界の内因性ペプチド物質市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の内因性ペプチド物質市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「神経ペプチド」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 内因性ペプチド物質のグローバル主要企業は、Assertio Therapeutics Inc.、 Cipher Pharmaceuticals Inc.、 Endo International Plc、 Biosynth Carbosynth、 Lannett Co. Inc.、 Pfizer、 Johnson & Johnson、 Peptide Institute、 Abbexa、 Phoenix Pharmaceuticals、 Creative Peptidesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、内因性ペプチド物質のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の内因性ペプチド物質市場：タイプ別、2018年-2023年、2024年-2029年 世界の内因性ペプチド物質市場：タイプ別市場シェア、2022年 ・神経ペプチド、ホルモン、サイトカイン、ペプチドホルモン、生理活性ペプチド 世界の内因性ペプチド物質市場：用途別、2018年-2023年、2024年-2029年 世界の内因性ペプチド物質市場：用途別市場シェア、2022年 ・研究、医療、その他 世界の内因性ペプチド物質市場：地域・国別、2018年-2023年、2024年-2029年 世界の内因性ペプチド物質市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における内因性ペプチド物質のグローバル売上、2018年-2023年 ・主要企業における内因性ペプチド物質のグローバル売上シェア、2022年 ・主要企業における内因性ペプチド物質のグローバル販売量、2018年-2023年 ・主要企業における内因性ペプチド物質のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Assertio Therapeutics Inc.、 Cipher Pharmaceuticals Inc.、 Endo International Plc、 Biosynth Carbosynth、 Lannett Co. Inc.、 Pfizer、 Johnson & Johnson、 Peptide Institute、 Abbexa、 Phoenix Pharmaceuticals、 Creative Peptides ************************************************************* ・調査・分析レポートの概要 内因性ペプチド物質市場の定義 市場セグメント 世界の内因性ペプチド物質市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の内因性ペプチド物質市場規模 世界の内因性ペプチド物質市場規模：2022年 VS 2029年 世界の内因性ペプチド物質市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの内因性ペプチド物質の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の内因性ペプチド物質製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：神経ペプチド、ホルモン、サイトカイン、ペプチドホルモン、生理活性ペプチド 内因性ペプチド物質のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：研究、医療、その他 内因性ペプチド物質の用途別グローバル売上・予測 ・地域別市場分析 地域別内因性ペプチド物質市場規模 2022年と2029年 地域別内因性ペプチド物質売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Assertio Therapeutics Inc.、 Cipher Pharmaceuticals Inc.、 Endo International Plc、 Biosynth Carbosynth、 Lannett Co. Inc.、 Pfizer、 Johnson & Johnson、 Peptide Institute、 Abbexa、 Phoenix Pharmaceuticals、 Creative Peptides ... |
This research report provides a comprehensive analysis of the Endogenous Peptide Substances market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Endogenous Peptide Substances market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Endogenous Peptide Substances, challenges faced by the industry, and potential opportunities for market players.
The global Endogenous Peptide Substances market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Endogenous Peptide Substances market presents opportunities for various stakeholders, including Research, Medicine. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Endogenous Peptide Substances market. Additionally, the growing consumer demand present avenues for market expansion.
The global Endogenous Peptide Substances market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people’s demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
Key Features:
The research report on the Endogenous Peptide Substances market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Endogenous Peptide Substances market.
Market Overview: The report provides a comprehensive overview of the Endogenous Peptide Substances market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Neuropeptides, Hormones), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Endogenous Peptide Substances market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Endogenous Peptide Substances market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Endogenous Peptide Substances market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Endogenous Peptide Substances market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Endogenous Peptide Substances market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Endogenous Peptide Substances market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Endogenous Peptide Substances, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Endogenous Peptide Substances market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Endogenous Peptide Substances market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Neuropeptides
Hormones
Cytokines
Peptide Hormones
Bioactive Peptides
Market segment by Application
Research
Medicine
Others
Global Endogenous Peptide Substances Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides
Outline of Major Chapters:
Chapter 1: Introduces the definition of Endogenous Peptide Substances, market overview.
Chapter 2: Global Endogenous Peptide Substances market size in revenue.
Chapter 3: Detailed analysis of Endogenous Peptide Substances company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Endogenous Peptide Substances in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Endogenous Peptide Substances Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Endogenous Peptide Substances Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Endogenous Peptide Substances Overall Market Size
2.1 Global Endogenous Peptide Substances Market Size: 2022 VS 2029
2.2 Global Endogenous Peptide Substances Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Endogenous Peptide Substances Players in Global Market
3.2 Top Global Endogenous Peptide Substances Companies Ranked by Revenue
3.3 Global Endogenous Peptide Substances Revenue by Companies
3.4 Top 3 and Top 5 Endogenous Peptide Substances Companies in Global Market, by Revenue in 2022
3.5 Global Companies Endogenous Peptide Substances Product Type
3.6 Tier 1, Tier 2 and Tier 3 Endogenous Peptide Substances Players in Global Market
3.6.1 List of Global Tier 1 Endogenous Peptide Substances Companies
3.6.2 List of Global Tier 2 and Tier 3 Endogenous Peptide Substances Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Endogenous Peptide Substances Market Size Markets, 2022 & 2029
4.1.2 Neuropeptides
4.1.3 Hormones
4.1.4 Cytokines
4.1.5 Peptide Hormones
4.1.6 Bioactive Peptides
4.2 By Type – Global Endogenous Peptide Substances Revenue & Forecasts
4.2.1 By Type – Global Endogenous Peptide Substances Revenue, 2018-2023
4.2.2 By Type – Global Endogenous Peptide Substances Revenue, 2024-2029
4.2.3 By Type – Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Endogenous Peptide Substances Market Size, 2022 & 2029
5.1.2 Research
5.1.3 Medicine
5.1.4 Others
5.2 By Application – Global Endogenous Peptide Substances Revenue & Forecasts
5.2.1 By Application – Global Endogenous Peptide Substances Revenue, 2018-2023
5.2.2 By Application – Global Endogenous Peptide Substances Revenue, 2024-2029
5.2.3 By Application – Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Endogenous Peptide Substances Market Size, 2022 & 2029
6.2 By Region – Global Endogenous Peptide Substances Revenue & Forecasts
6.2.1 By Region – Global Endogenous Peptide Substances Revenue, 2018-2023
6.2.2 By Region – Global Endogenous Peptide Substances Revenue, 2024-2029
6.2.3 By Region – Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Endogenous Peptide Substances Revenue, 2018-2029
6.3.2 US Endogenous Peptide Substances Market Size, 2018-2029
6.3.3 Canada Endogenous Peptide Substances Market Size, 2018-2029
6.3.4 Mexico Endogenous Peptide Substances Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Endogenous Peptide Substances Revenue, 2018-2029
6.4.2 Germany Endogenous Peptide Substances Market Size, 2018-2029
6.4.3 France Endogenous Peptide Substances Market Size, 2018-2029
6.4.4 U.K. Endogenous Peptide Substances Market Size, 2018-2029
6.4.5 Italy Endogenous Peptide Substances Market Size, 2018-2029
6.4.6 Russia Endogenous Peptide Substances Market Size, 2018-2029
6.4.7 Nordic Countries Endogenous Peptide Substances Market Size, 2018-2029
6.4.8 Benelux Endogenous Peptide Substances Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Endogenous Peptide Substances Revenue, 2018-2029
6.5.2 China Endogenous Peptide Substances Market Size, 2018-2029
6.5.3 Japan Endogenous Peptide Substances Market Size, 2018-2029
6.5.4 South Korea Endogenous Peptide Substances Market Size, 2018-2029
6.5.5 Southeast Asia Endogenous Peptide Substances Market Size, 2018-2029
6.5.6 India Endogenous Peptide Substances Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Endogenous Peptide Substances Revenue, 2018-2029
6.6.2 Brazil Endogenous Peptide Substances Market Size, 2018-2029
6.6.3 Argentina Endogenous Peptide Substances Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Endogenous Peptide Substances Revenue, 2018-2029
6.7.2 Turkey Endogenous Peptide Substances Market Size, 2018-2029
6.7.3 Israel Endogenous Peptide Substances Market Size, 2018-2029
6.7.4 Saudi Arabia Endogenous Peptide Substances Market Size, 2018-2029
6.7.5 UAE Endogenous Peptide Substances Market Size, 2018-2029
7 Endogenous Peptide Substances Companies Profiles
7.1 Assertio Therapeutics Inc.
7.1.1 Assertio Therapeutics Inc. Company Summary
7.1.2 Assertio Therapeutics Inc. Business Overview
7.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Major Product Offerings
7.1.4 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.1.5 Assertio Therapeutics Inc. Key News & Latest Developments
7.2 Cipher Pharmaceuticals Inc.
7.2.1 Cipher Pharmaceuticals Inc. Company Summary
7.2.2 Cipher Pharmaceuticals Inc. Business Overview
7.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Major Product Offerings
7.2.4 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.2.5 Cipher Pharmaceuticals Inc. Key News & Latest Developments
7.3 Endo International Plc
7.3.1 Endo International Plc Company Summary
7.3.2 Endo International Plc Business Overview
7.3.3 Endo International Plc Endogenous Peptide Substances Major Product Offerings
7.3.4 Endo International Plc Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.3.5 Endo International Plc Key News & Latest Developments
7.4 Biosynth Carbosynth
7.4.1 Biosynth Carbosynth Company Summary
7.4.2 Biosynth Carbosynth Business Overview
7.4.3 Biosynth Carbosynth Endogenous Peptide Substances Major Product Offerings
7.4.4 Biosynth Carbosynth Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.4.5 Biosynth Carbosynth Key News & Latest Developments
7.5 Lannett Co. Inc.
7.5.1 Lannett Co. Inc. Company Summary
7.5.2 Lannett Co. Inc. Business Overview
7.5.3 Lannett Co. Inc. Endogenous Peptide Substances Major Product Offerings
7.5.4 Lannett Co. Inc. Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.5.5 Lannett Co. Inc. Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Endogenous Peptide Substances Major Product Offerings
7.6.4 Pfizer Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Johnson & Johnson
7.7.1 Johnson & Johnson Company Summary
7.7.2 Johnson & Johnson Business Overview
7.7.3 Johnson & Johnson Endogenous Peptide Substances Major Product Offerings
7.7.4 Johnson & Johnson Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.7.5 Johnson & Johnson Key News & Latest Developments
7.8 Peptide Institute
7.8.1 Peptide Institute Company Summary
7.8.2 Peptide Institute Business Overview
7.8.3 Peptide Institute Endogenous Peptide Substances Major Product Offerings
7.8.4 Peptide Institute Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.8.5 Peptide Institute Key News & Latest Developments
7.9 Abbexa
7.9.1 Abbexa Company Summary
7.9.2 Abbexa Business Overview
7.9.3 Abbexa Endogenous Peptide Substances Major Product Offerings
7.9.4 Abbexa Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.9.5 Abbexa Key News & Latest Developments
7.10 Phoenix Pharmaceuticals
7.10.1 Phoenix Pharmaceuticals Company Summary
7.10.2 Phoenix Pharmaceuticals Business Overview
7.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Major Product Offerings
7.10.4 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.10.5 Phoenix Pharmaceuticals Key News & Latest Developments
7.11 Creative Peptides
7.11.1 Creative Peptides Company Summary
7.11.2 Creative Peptides Business Overview
7.11.3 Creative Peptides Endogenous Peptide Substances Major Product Offerings
7.11.4 Creative Peptides Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.11.5 Creative Peptides Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
